Welcome to the CRD Databases

Website Redesign

Welcome to the new interface for the CRD databases.

The new design and layout features enhanced filtering, searching, display and linking facilities all making our content easier to find and share with others.

DARE, NHS EED and HTA

High quality evidence to inform decision-making can be difficult to access, identify and appraise. Our databases provide access to:

21,000 systematic reviews
11,000 economic evaluations
10,000 health technology assessments

Most viewed records

The 5 most frequently viewed records in the last month are:

1. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

2. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase

3. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review

4. Imatinib mesylate for chronic myeloid leukemia: what do we really know?

5. Imatinib (Glivec) for Philadelphia positive acute lymphoblastic leukaemia - horizon scanning review